Legend Biotech Projects 2026 Operating Profit Amid Strong CARVYKTI® Growth and Pipeline Progress
Summary
Legend Biotech anticipates achieving operating profit in 2026, driven by the strong market leadership and expanding manufacturing capacity of its flagship CAR-T therapy, CARVYKTI®, alongside promising pipeline advancements.
Key Events
-
Projected Profitability
The company expects to achieve company-wide operating profit in 2026, marking a significant financial inflection point.
-
CARVYKTI® Market Leadership
CARVYKTI® has treated over 10,000 patients, achieved NCCN Category 1 designation, and boasts a 10,000 annualized dose capacity by 2026.
-
Pipeline Advancement
Patients have been dosed for IIT In Vivo CAR-T studies in 2025, with plans to file 1-2 US INDs in the second half of 2026.
-
Manufacturing Scale-Up
All CARVYKTI® manufacturing sites are now online, with a 97% success rate and a median turnaround time of less than 30 days.
Analysis
Legend Biotech's corporate presentation at the J.P. Morgan Healthcare Conference outlines a robust outlook, projecting company-wide operating profit in 2026. This financial milestone is supported by the strong commercial performance of CARVYKTI®, which has treated over 10,000 patients and achieved NCCN Category 1 designation. The company is also expanding manufacturing capacity and advancing its pipeline, including in vivo CAR-T studies and plans for new INDs, signaling continued innovation and growth.
At the time of this filing, LEGN was trading at $23.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $20.21 to $45.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.